

**Agenda**  
**DCVMN Regulatory WG Workshop**  
**Brussels, Belgium**  
**19-20 June, 2024**

**Objectives:**

1. To explain the industry CMC responsible and regulatory WG members what the advantages are of NGS.
2. To provide a Regulatory landscape (WHO, FDA, ICHQ5A, European Pharmacopoeia...)

**Day 1, 19<sup>th</sup> June, 2024**

**Chairpersons: Vipul Doshi**

Time	Topic	Presenter
9:00–9:15	Welcome	Rajinder Suri
9:15–9:45	Keynote lecture	Johannes Blümel Paul-Ehrlich-Institut
9:45–10:15	Illumina	Francois Cesbron & Vincent Stevens
10:15–10:45	<i>Coffee Break</i>	
10:45–11:15	Nanopore Oxford	Glen Monroe
11:15–12:15	Thermo Fisher	Caroline Rossel
12:15–12:45	WHO: “High Throughput Sequencing in the context of WHO Biological Standardization”	Ivana Knezevic
12:45–13:45	<i>Lunch</i>	
14:00–18:00	Visit of Sciensano (Belgian OMCL using NGS in daily practice) in 3 groups)	All
19:00 onwards	Dinner	

**Day 2, 20<sup>th</sup> June 2024**

**Chairpersons: Dieter Deforce & Pieter Neels**

Time	Topic	Presenter
9:00–9:05	Opening of day 2	Rajinder Suri
9:05–9:20	Introduction to regulatory issues for implementing NGS	Koen Brusselmans Sciensano
9:20–9:35	Introduction to regulatory issues for implementing NGS	Gibran Rubio Quintanares Paul-Ehrlich-Institut

<b>9:35-9:50</b>	Introduction to regulatory issues for implementing NGS	Michael Wall Health Canada
<b>9:50-10:00</b>	Q&A first session	all
<b>10:00-10:15</b>	Viewpoint from vaccine industry	Noemie Deneyer GSK
<b>10:15-10:30</b>	Viewpoint from vaccine industry	Carine Logvinoff Sanofi Pasteur
<b>10:30-10:40</b>	Q&A second session	
<b>10:40-11:00</b>	<i>Coffee break</i>	
<b>11:00-11:15</b>	Viewpoint from DCVMN members Dr. T .M Chozhavel Rajanathan	Zydus
<b>11:15-11:30</b>	Viewpoint from DCVMN members Mr Sharanabasava	Serum Institute India
<b>11:30-11:45</b>	Q&A	All
<b>11:45-13:00</b>	Round table discussion	All
<b>13:00-14:00</b>	Lunch	